Dopamine D3/D2 Receptor Antagonist PF-4363467 Attenuates Opioid Drug-Seeking Behavior without Concomitant D2 Side Effects

• Published in: ACS chemical neuroscience Vol. 8; no. 1
• Main Authors: Wager, Travis T., Chappie, Thomas, Horton, David, Chandrasekaran, Ramalakshmi Y., Samas, Brian, Dunn-Sims, Elizabeth R., Hsu, Cathleen, Nawreen, Nawshaba, Vanase-Frawley, Michelle A., O’Connor, Rebecca E., Schmidt, Christopher J., Dlugolenski, Keith, Stratman, Nancy C., Majchrzak, Mark J., Kormos, Bethany L., Nguyen, David P., Sawant-Basak, Aarti, Mead, Andy N.
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society (ACS) 10.10.2016
• Subjects: 60 APPLIED LIFE SCIENCES; Antagonists; Central nervous system; cessation; CNS MPO; dopamine D2 antagonist; dopamine D3 antagonist; drug addiction; drug-seeking behavior; extrapyramidal symptoms; INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CHEMISTRY; locomotor; opioid; Pharmaceuticals; Receptors; reinstatement; Rodent models; Substance use dependence

Dopamine receptor antagonism is a compelling molecular target for the treatment of a range of psychiatric disorders, including substance use disorders. From our corporate compound file, we identified a structurally unique D3 receptor (D3R) antagonist scaffold, 1. Through a hybrid approach, we merged...